Abstract
Cisplatin is widely used in cancer treatment, but the application is limited due to toxicities and its acquired resistance. In this study, we delivered cisplatin to prostate cancer cells by linking the platinum prodrug Pt(IV) to melanin-like nanoparticles (MeNPs), a promising photothermal therapeutic agent with excellent biocompatibility. As expected, the Pt(IV)-MeNPs exhibited brilliant synergic photothermal-chemotherapy upon near-infrared reflection exposure. Compared with free cisplatin, Pt(IV)-MeNPs displayed highly effective antitumour activity both in vitro and in vivo.
Funding Information
  • National Natural Science Foundation of China (81772710)
  • National Natural Science Foundation of China (81572519)
  • Project of Invigorating Health Care through Science, Technology and Education Jiangsu Provincial Key Medical Discipline, the Social Development Project of Nanjing (201503014)